Rajesh S Alphonse1, Arul Vadivel1, Moses Fung1, William Chris Shelley1, Paul John Critser1, Lavinia Ionescu1, Megan O'Reilly1, Robin K Ohls1, Suzanne McConaghy1, Farah Eaton1, Shumei Zhong1, Merv Yoder1, Bernard Thébaud2. 1. From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.). 2. From the Department of Pediatrics, Women and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Canada (R.S.A., M.F., L.I. M.O., F.E.); Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Center for Stem Cell Research, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (A.V., S.Z., B.T.); Department of Pediatrics, Herman B Wells Center for Pediatrics Research, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, IN (W.C.S., P.J.C., M.Y.); and Department of Pediatrics, University of New Mexico, Albuquerque, NM (R.K.O., S.M.). bthebaud@ohri.
Abstract
BACKGROUND: Bronchopulmonary dysplasia and emphysema are life-threatening diseases resulting from impaired alveolar development or alveolar destruction. Both conditions lack effective therapies. Angiogenic growth factors promote alveolar growth and contribute to alveolar maintenance. Endothelial colony-forming cells (ECFCs) represent a subset of circulating and resident endothelial cells capable of self-renewal and de novo vessel formation. We hypothesized that resident ECFCs exist in the developing lung, that they are impaired during arrested alveolar growth in experimental bronchopulmonary dysplasia, and that exogenous ECFCs restore disrupted alveolar growth. METHODS AND RESULTS: Human fetal and neonatal rat lungs contain ECFCs with robust proliferative potential, secondary colony formation on replating, and de novo blood vessel formation in vivo when transplanted into immunodeficient mice. In contrast, human fetal lung ECFCs exposed to hyperoxia in vitro and neonatal rat ECFCs isolated from hyperoxic alveolar growth-arrested rat lungs mimicking bronchopulmonary dysplasia proliferated less, showed decreased clonogenic capacity, and formed fewer capillary-like networks. Intrajugular administration of human cord blood-derived ECFCs after established arrested alveolar growth restored lung function, alveolar and lung vascular growth, and attenuated pulmonary hypertension. Lung ECFC colony- and capillary-like network-forming capabilities were also restored. Low ECFC engraftment and the protective effect of cell-free ECFC-derived conditioned media suggest a paracrine effect. Long-term (10 months) assessment of ECFC therapy showed no adverse effects with persistent improvement in lung structure, exercise capacity, and pulmonary hypertension. CONCLUSIONS: Impaired ECFC function may contribute to arrested alveolar growth. Cord blood-derived ECFC therapy may offer new therapeutic options for lung diseases characterized by alveolar damage.
BACKGROUND:Bronchopulmonary dysplasia and emphysema are life-threatening diseases resulting from impaired alveolar development or alveolar destruction. Both conditions lack effective therapies. Angiogenic growth factors promote alveolar growth and contribute to alveolar maintenance. Endothelial colony-forming cells (ECFCs) represent a subset of circulating and resident endothelial cells capable of self-renewal and de novo vessel formation. We hypothesized that resident ECFCs exist in the developing lung, that they are impaired during arrested alveolar growth in experimental bronchopulmonary dysplasia, and that exogenous ECFCs restore disrupted alveolar growth. METHODS AND RESULTS:Human fetal and neonatal rat lungs contain ECFCs with robust proliferative potential, secondary colony formation on replating, and de novo blood vessel formation in vivo when transplanted into immunodeficientmice. In contrast, human fetal lung ECFCs exposed to hyperoxia in vitro and neonatal rat ECFCs isolated from hyperoxic alveolar growth-arrested rat lungs mimicking bronchopulmonary dysplasia proliferated less, showed decreased clonogenic capacity, and formed fewer capillary-like networks. Intrajugular administration of human cord blood-derived ECFCs after established arrested alveolar growth restored lung function, alveolar and lung vascular growth, and attenuated pulmonary hypertension. Lung ECFC colony- and capillary-like network-forming capabilities were also restored. Low ECFC engraftment and the protective effect of cell-free ECFC-derived conditioned media suggest a paracrine effect. Long-term (10 months) assessment of ECFC therapy showed no adverse effects with persistent improvement in lung structure, exercise capacity, and pulmonary hypertension. CONCLUSIONS: Impaired ECFC function may contribute to arrested alveolar growth. Cord blood-derived ECFC therapy may offer new therapeutic options for lung diseases characterized by alveolar damage.
Authors: Christopher D Baker; Vivek Balasubramaniam; Peter M Mourani; Marci K Sontag; Claudine P Black; Sharon L Ryan; Steven H Abman Journal: Eur Respir J Date: 2012-04-10 Impact factor: 16.671
Authors: Vivek Balasubramaniam; Sharon L Ryan; Gregory J Seedorf; Emily V Roth; Thatcher R Heumann; Mervin C Yoder; David A Ingram; Christopher J Hogan; Neil E Markham; Steven H Abman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-12-11 Impact factor: 5.464
Authors: P M Wong; A N Lees; J Louw; F Y Lee; N French; K Gain; C P Murray; A Wilson; D C Chambers Journal: Eur Respir J Date: 2008-04-02 Impact factor: 16.671
Authors: Timothy van Haaften; Roisin Byrne; Sebastien Bonnet; Gael Y Rochefort; John Akabutu; Manaf Bouchentouf; Gloria J Rey-Parra; Jacques Galipeau; Alois Haromy; Farah Eaton; Ming Chen; Kyoko Hashimoto; Doris Abley; Greg Korbutt; Stephen L Archer; Bernard Thébaud Journal: Am J Respir Crit Care Med Date: 2009-08-27 Impact factor: 21.405
Authors: Hideshi Fujinaga; Christopher D Baker; Sharon L Ryan; Neil E Markham; Gregory J Seedorf; Vivek Balasubramaniam; Steven H Abman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-09-04 Impact factor: 5.464
Authors: Christopher D Baker; Sharon L Ryan; David A Ingram; Gregory J Seedorf; Steven H Abman; Vivek Balasubramaniam Journal: Am J Respir Crit Care Med Date: 2009-05-29 Impact factor: 21.405
Authors: Yuangsheng Gao; David N Cornfield; Kurt R Stenmark; Bernard Thébaud; Steven H Abman; J Usha Raj Journal: Pulm Circ Date: 2016-12 Impact factor: 3.017
Authors: Susumu Sakimoto; Valentina Marchetti; Edith Aguilar; Kelsey Lee; Yoshihiko Usui; Salome Murinello; Felicitas Bucher; Jennifer K Trombley; Regis Fallon; Ravenska Wagey; Carrie Peters; Elizabeth L Scheppke; Peter D Westenskow; Martin Friedlander Journal: JCI Insight Date: 2017-01-26